IAG . Bankinter Fija su Precio Objetivo en 3,50€ Por Acción . En Marcha la Recompra de Acciones .
05 febrero 2010
Reuters India : Zeltia cancer drug approved in eight more countries .
... Yondelis is a key product for the loss-making Spanish company, which forecasts that sales of the drug could reach 300 million euros ($420.3 million) a year in Europe. ...
‹
›
Inicio
Ver versión web